Literature DB >> 2250866

Visual results and complications of transsclerally sutured intraocular lenses in penetrating keratoplasty.

D G Heidemann1, S P Dunn.   

Abstract

We retrospectively reviewed the charts of 56 consecutive patients who had undergone penetrating keratoplasty with transscleral fixation of a posterior chamber intraocular lens. Follow-up ranged from 3 to 28 months (mean, 11.1 months). Postoperative visual acuity improved in 46 patients (82%), remained the same in eight (14%), and worsened in two (3.6%). In 32 patients with at least 10 months' follow-up, best corrected visual acuity as measured with a pinhole or hard contact lens was 20/40 or better in 12 (38%), 20/50 to 20/10 in 10 (31%), and 20/200 or worse in 10 (31%). Problems with lens decentration, tilt, or scleral suture-related infections were minimal. Glaucoma was the msot common cause of decreased vision in patients with 10 or more months' follow-up. Three patients (5.4%) developed rhegmatogenous retinal detachments early in the postoperative course.

Entities:  

Mesh:

Year:  1990        PMID: 2250866

Source DB:  PubMed          Journal:  Ophthalmic Surg        ISSN: 0022-023X


  3 in total

1.  Long-term safety and visual outcomes of transscleral sutured posterior chamber IOLs and penetrating keratoplasty combined with transscleral sutured posterior chamber IOLs.

Authors:  Jennifer Marie Nottage; Vikram Bhasin; Verinder S Nirankari
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

2.  Implantation of retropupillar iris claw lenses with and without combined penetrating keratoplasty.

Authors:  Florian Rüfer; Mark Saeger; Bernhard Nölle; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-12       Impact factor: 3.117

3.  Implantation of scleral fixated sutured posterior chamber lenses: a retrospective analysis of 119 cases.

Authors:  Lothar Krause; Nikolaos E Bechrakis; Heinrich Heimann; Stefan Salditt; Michael H Foerster
Journal:  Int Ophthalmol       Date:  2008-04-10       Impact factor: 2.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.